Researchers reported that irosustat, a steroid sulfatase inhibitor, and its target cholesterol sulfate inhibit drug-resistant Plasmodium falciparum through a host-directed mechanism. In mouse malaria models, the study described strong oral efficacy, positioning the approach as a potential pathway to circumvent resistance driven by parasite-centric targets.